Develops innovative products for women's reproductive health and sexual wellness.
Symbol: | DARE |
---|---|
Quote: | 3.17 |
Change: | +0.01 |
Change %: | +0.32% |
High: | 3.25 |
Low: | 3.13 |
Open: | 3.14 |
---|---|
Volume: | 54,927 |
52 Week: | 2.67-7.56 |
P/E Ratio: | -5.47 |
EPS: | -0.58 |
Market Cap: | 27.58 M |
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to enhancing women's health through the development and commercialization of innovative therapies. Focused on areas such as contraception, fertility, and sexual and vaginal health, Dare Bioscience identifies and advances novel product candidates to address unmet needs in these critical areas of women's healthcare.
The company's current flagship product, XACIATO, is a single-dose vaginal gel prescribed for the treatment of bacterial vaginosis in females aged 12 years and older. Dare Bioscience also boasts an impressive pipeline of advanced clinical products. Notable candidates include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a topical cream formulation of sildenafil designed to treat female sexual arousal disorder when applied to the vulva and vagina.
In addition to its advanced clinical portfolio, Dare Bioscience is progressing several Phase 1-ready products. These include DARE-HRT1, an intravaginal ring combining bio-identical estradiol and progesterone for the treatment of vasomotor symptoms associated with hormone therapy; and DARE-VVA1, a vaginally delivered tamoxifen formulation aimed at addressing vulvar and vaginal atrophy in hormone-receptor positive breast cancer patients. With a robust pre-clinical pipeline as well, Dare Bioscience continues to innovate with products like DARE-LARC1, a combination contraceptive product offering reversible contraception, and DARE-RH1, a non-hormonal contraceptive for both men and women.
Exchange: | NASDAQ |
---|---|
Beta: | 1.318 |
Industry: | Biotechnology |
Sector: | Healthcare |
Employees: | 23 |
IPO Date: | Apr 10, 2014 |
![]() DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management 16 days ago |
![]() The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health. 1 months ago |
![]() Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - JonesTrading Brian Kemp Dolliver - Brookline Capital Markets Douglas Tsao - H.C. Wainwright Operator Welcome t... 3 months ago |
![]() Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $1.08 per share a year ago. 3 months ago |
![]() Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the numb... 3 months ago |